![Frontiers | Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma Frontiers | Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma](https://www.frontiersin.org/files/Articles/851864/fonc-12-851864-HTML-r1/image_m/fonc-12-851864-t001.jpg)
Frontiers | Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma
![Frontiers | Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma Frontiers | Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma](https://www.frontiersin.org/files/Articles/851864/fonc-12-851864-HTML-r1/image_m/fonc-12-851864-t003.jpg)
Frontiers | Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma
![Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial | Blood Cancer Journal Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial | Blood Cancer Journal](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41408-021-00498-0/MediaObjects/41408_2021_498_Fig1_HTML.png)
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial | Blood Cancer Journal
![Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology](https://www.annalsofoncology.org/cms/asset/20a399c7-1c22-415f-8045-584116cd4b63/gr3.jpg)
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology
Indications & Dosing | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
Indications & Dosing | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
![Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis | Advances in Therapy Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis | Advances in Therapy](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12325-020-01521-9/MediaObjects/12325_2020_1521_Fig1_HTML.png)
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis | Advances in Therapy
![PLEIADES study design. a Assessed using next-generation sequencing. CR,... | Download Scientific Diagram PLEIADES study design. a Assessed using next-generation sequencing. CR,... | Download Scientific Diagram](https://www.researchgate.net/publication/343338285/figure/fig1/AS:933700225204224@1599622889659/PLEIADES-study-design-a-Assessed-using-next-generation-sequencing-CR-complete.png)
PLEIADES study design. a Assessed using next-generation sequencing. CR,... | Download Scientific Diagram
![Infusion-related reactions in D-VRd, D-VMP and D-Rd in PLEIADES DARA SC... | Download Scientific Diagram Infusion-related reactions in D-VRd, D-VMP and D-Rd in PLEIADES DARA SC... | Download Scientific Diagram](https://www.researchgate.net/publication/343338285/figure/fig2/AS:933700225220608@1599622889690/Infusion-related-reactions-in-D-VRd-D-VMP-and-D-Rd-in-PLEIADES-DARA-SC-cohorts-versus.png)
Infusion-related reactions in D-VRd, D-VMP and D-Rd in PLEIADES DARA SC... | Download Scientific Diagram
![Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma - Larysa Sanchez, Joshua Richter, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Samir Parekh, Shambavi Richard, Lowena Tam, Daniel Verina, Ajai Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma - Larysa Sanchez, Joshua Richter, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Samir Parekh, Shambavi Richard, Lowena Tam, Daniel Verina, Ajai](https://journals.sagepub.com/cms/10.1177/2040620720987075/asset/images/large/10.1177_2040620720987075-fig2.jpeg)